At Compugen, we are committed to discovering and developing groundbreaking therapies that unlock the power of the immune system to fight cancers.
To support us in the mission, we are continually seeking collaborations and strategic partnerships with leading biopharma companies worldwide to advance our early- and clinical-stage programs and bring transformational medicines that make a difference to patients.
If you would like to learn more about partnering with Compugen, please contact us at firstname.lastname@example.org.
Compugen and Bayer are engaged in a collaboration and license agreement for the research, development and commercialization of immuno-oncology therapeutics against ILDR2, a novel immune checkpoint discovered computationally by Compugen.
Currently BAY 1905254, the lead antibody targeting ILDR2, is being evaluated in a Phase 1 study in patients with advanced solid tumors. The study, sponsored and conducted by Bayer, is an open-label, dose escalation study designed to evaluate the safety and tolerability of BAY 1905254 as monotherapy and in combination with Keytruda® (pembrolizumab). The expansion of the Phase 1 study will evaluate the combination in IO naïve first line head and neck squamous cell carcinoma patients. Additional information on the Phase 1 study can be found here.
Compugen received over $30 million in upfront, preclinical and clinical milestone payments under the agreement between the two companies and is eligible to receive over $250 million in future milestone payments, as well as tiered royalties on global sales.
Bristol Myers Squibb
Clinical Trial Collaboration and Equity Investment October 2018- August 2022
The collaboration concluded following Compugen’s decision to focus on COM701 and COM902 combinations and wind down the Phase 1 program conducted as part of this collaboration.
Under the collaboration with Bristol Myers Squibb, the parties evaluated the safety, tolerability and preliminary antitumor activity of Compugen’s COM701, an anti-PVRIG antibody, in combination with Bristol Myers Squibb’s PD-1 immune checkpoint inhibitor Opdivo® (nivolumab) and also in combination with Opdivo® (nivolumab) and with Bristol Myers Squibb’s investigational anti-TIGIT antibody, BMS-986207, in patients with advanced solid tumors. The collaboration was based on Compugen’s discovery of a novel immune checkpoint, PVRIG, as well as extensive preclinical studies that PVRIG signaling is synergistic with the PD-1 pathway to suppress immune cell activity. The Phase 1 trial was sponsored by Compugen and Bristol Myers Squibb provided Opdivo and BMS-986207 at no cost. More information on the trial can be found here and here.
In conjunction with this collaboration, Bristol Myers Squibb made a $12M initial strategic equity investment in Compugen in 2018 and an additional $20M strategic equity investment in 2021.
Compugen entered into an exclusive license agreement with AstraZeneca for the development and commercialization of bispecific and multi-specific antibody products derived from COM902. Bispecific and multi-specific antibodies represent an emerging class of cancer therapeutics with the potential to improve response rates. AstraZeneca can create multiple products under this license and has sole responsibility for research, development and commercial activities of these products.
In return for the license granted, Compugen received $18 million in upfront and milestone payments to date and is eligible to receive up to $200 million in milestone payments for the first product, as well as payments for additional products and tiered royalties on global sales. AZD2936, a TIGIT/PD-1 bispecific is in Phase 1/2 development.
Johns Hopkins University
Compugen has an ongoing research collaboration with Johns Hopkins University, under the direction of renowned immuno-oncology expert and pioneer, Drew Pardoll M.D., Ph.D. Dr. Pardoll’s work in immune regulation, particularly related to mechanisms by which cancer cells evade elimination by the immune system, spans decades and has led to major advancements in the field of immuno-oncology. This highly valuable collaborative effort provides experimental insight into the biology and mechanisms of action of Compugen’s novel cancer immunotherapy targets and accelerates their expected translation towards the clinic.
Prostate Cancer Foundation
To advance our research on a novel myeloid target computationally-discovered by Compugen as a new potential immunotherapy target, Compugen has a collaboration with the Prostate Cancer Foundation (PCF). Under this collaboration, we provided funding for a PCF Challenge Award, an award designed to fund ambitious new science to advance treatment options for prostate cancer. Challenge Award winners are selected through a peer-review process conducted by the PCF Standing Review Committee.
This PCF Challenge award was granted to Dr. Jelani Chinelo Zarif, M.S., Ph.D., Assistant Professor of Oncology and Drew Pardoll, M.D., Ph.D., Professor of Oncology, both at Johns Hopkins University. The three-year research program will evaluate the function of a novel immune-modulatory checkpoint, which is expressed on myeloid cells and macrophages in various cancers, including prostate cancer. The project is intended to further validate the Compugen computationally-discovered target in a preclinical setting, alongside the internal R&D work at Compugen, and provide the scientific foundation to develop a new therapeutic agent against this target and advance it to the clinic.